ECD is an uncommon, non-inherited, multiorgan non-Langerhans cell histiocytosis, with an unknown pathogenesis. It is commonly diagnosed in middle-aged people, with a marginal male predilection. Pathologically, this disease is characterized by the infiltration of lipid-laden histiocytes, Touton giant cells, and a variable extent of background fibrosis. In the immunohistochemical tissue study, the histiocytes stained positive for CD68, whereas S-100 and CD1 were negative, unlike Langerhans cell histiocytosis (LCH). Moreover, it is associated with BRAF V600E mutations (
2). The concurrence of ECD with LCH with double infiltration of various cells has been also reported (
3-
5).
ECD usually presents with a range of non-specific manifestations; however, the most common presenting symptom is bone pain, followed by bilateral, symmetric metaphyseal, and diaphyseal sclerosis of the long bones in the majority of patients (
6). Rarely, patients show clinical symptoms, such as gastrointestinal involvement, and misdiagnosis can contribute to several futile medical treatments. Symmetric osteosclerosis of long tubular bones has been reported in mastocytosis, lymphoma, myeloid metaplasia, and metastasis (
6,
7). Nevertheless, this finding is a classic sign to confirm the diagnosis of ECD, along with the characteristic histopathological results (
1,
2).
Additionally, more than half of ECD patients have extraskeletal manifestations, such as retroperitoneal fibrosis, orbital infiltration, interstitial lung disease, bilateral adrenal involvement, testicular infiltration, and breast, central nervous system, and/or cardiovascular system involvement (
8). It is known that fat infiltration and high levels of foamy histiocytes around the retroperitoneal structure are the main causes of retroperitoneal involvement. Besides, the associated fibrosis results in perirenal and/or ureteral obstruction, as well as renal problems; nearly 29 - 59% of patients with ECD experience this problem (
6,
9).
In contrast, a small number of patients experience hepatic, pancreatic, mesenteric, and gastrointestinal tract problems (
1,
2,
4). Considering our patient’s symptoms, such as reduced appetite, persistent nausea, and considerable weight loss, the diagnosis of ECD was challenging. Generally, all cases of ECD require tissue biopsy under imaging guidance (ultrasound or CT) using a percutaneous approach to confirm the diagnosis and detect related mutations to achieve the treatment goals. The omental biopsy of the patient confirmed omental involvement by infiltration of foamy cell sheets mixed occasionally with Touton giant cells that were positive for CD68 (a histiocyte marker) and negative for S100, Langerin, and cytokeratin.
Moreover, our patient had characteristics consistent with skeletal involvement. The radiological survey revealed the increased density of the long bones. Retroperitoneal involvement was another characteristic of ECD in our case. Among formerly reported cases of ECD, the present case is unique, because despite his characteristic histological and radiological findings that confirmed the diagnosis of ECD, the initial gastrointestinal manifestations of ECD, indicating omental caking in abdominal CT scans, differed from those described in the literature.
The mortality rate of ECD is high. Among patients with a diagnosis of ECD, oral corticosteroids are common treatments; however, recent studies have reported the positive effects of interferon-based therapy on increasing patient survival (
10,
11). Pulmonary fibrosis and cardiac failure are major causes of mortality, and it is believed that the extent and distribution of extraskeletal involvement have a major contribution to prognosis. In our case, treatment was initiated with subcutaneous interferon-α (3,000,000 units three times per week). After six weeks, his clinical condition improved relatively. He is currently receiving follow-up care by our clinical team.
In conclusion, ECD is an uncommon, non-familial, multisystem, non-Langerhans cell histiocytosis, with various manifestations of highly variable severity. Extraskeletal manifestations also occur and predict a poor prognosis.